Key clinical milestones achieved, including first clinical study completion and initial clinical image publication. Net loss narrowed year-over-year, with cash position improved and financial runway extended to December 2025. Market outlook remains strong, with first revenues expected soon.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.